PF-5274857

1373615-35-0

C20H25ClN4O3S

DMSO : 125 mg/mL (286.07 mM; Need ultrasonic)

Stem Cell/Wnt

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood�brain barrier. IC50 value: 5.8 nM Target: Smoothened in vitro: PF-5274857 completely inhibits Shh-induced Hh pathway activity with IC50 of 2.7 nM measured by the transcriptional activity of Smo downstream gene Gli1 in MEF cells. The u-opioid receptor is weakly inhibited by PF-5274857 with a dissociation constant of 36 uM subsequently determined in a functional assay [1]. in vivo: PF-5274857 shows significant dose-dependent tumor growth inhibition (TGI) and induces tumor regression at high doses(>10 mg/kg)., PF-5274857 downregulates Gli1, Gli2, Ptch1, and Ptch2 gene expression levels to various degrees with maximal effects being achieved between 6 and 12 hours post-dose (Gli1 is the most sensitive gene), whereas PF-5274857 has little effect on Smo levels. In skin tissue, downregulation of Gli1 and Gli2 is also observed with a similar time course by PF-5274857. The model-derived drug concentration for half maximal inhibition of the tumor Gli1 mRNA production rate (IC50) by PF-5274857 is determined to be 8.9 nM in the Ptch+/ p53+/ medulloblastoma allograft mice, which mathematically corresponds to tumor regression of 119% TGI after 6 days of plasma exposure at this concentration. In the Ptch+/ p53 / medulloblastoma allograft mice, the IC50 value is estimated to be 3.5 nM, consistent with the Ptch+/ p53+/ results. PF-5274857 is also able to cross the blood�brain barrier in rats within 4 hours post-dose [1].